You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 145 No. 9, September 1991 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

The Effect of Valproic Acid on Plasma Carnitine Levels

Grzegorz Opala, MD, PhD; Susan Winter, MD; Carol Vance, MD; Hugh Vance, PhD; H. Terry Hutchison, MD, PhD; Lawrence S. Linn

Am J Dis Child. 1991;145(9):999-1001.


Abstract

• Plasma total, free, and acyl carnitine levels were determined in four groups of children: (1) those treated with valproic acid as monotherapy (n = 43), (2) those treated with valproic acid plus other antiepileptics as polytherapy (n = 91), (3) those treated with other antiepileptic drugs alone (n = 43), and (4) normal patients (n = 89). The mean free carnitine level was significantly lower in both the valproic acid monotherapy (29.9 µmol/L) and polytherapy (21.4 µmol/L) groups compared with normal subjects (36.8 µmol/L); it was also significantly lower than that in patients treated with other antiepileptic drugs (36.7 µmol/L). Comparison of valproic acid polytherapy and monotherapy yielded significantly lower free carnitine levels in the polytherapy group. The ratios of acyl to free carnitine for monotherapy (0.41) and polytherapy (0.45) were significantly higher than that in the normal group (0.25). This study indicates that a general decrease in the carnitine pool should be anticipated in patients taking valproic acid polytherapy and, to a lesser degree, monotherapy. Carnitine levels in the group taking other drugs did not differ from normal.

(AJDC. 1991;145:999-1001)



Author Affiliations

From Metabolic Research and Analysis Inc, Fresno, Calif (Drs Opala and H. Vance and Mr Linn), and Valley Children's Hospital and University of California, San Francisco, Fresno (Drs Winter, C. Vance, and Hutchison).


Footnotes

Accepted for publication April 22, 1991.

Reprint requests to Metabolic Research and Analysis Inc, 3150 E Shields Ave 104, Fresno, CA 93726 (Dr Opala).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Serum and Muscle Carnitine Levels in Epileptic Children Receiving Sodium Valproate
Anil et al.
J Child Neurol 2009;24:80-86.
ABSTRACT  

Serum Carnitine Levels During Oxcarbazepine and Carbamazepine Monotherapies in Children With Epilepsy
Kurul et al.
J Child Neurol 2003;18:552-554.
ABSTRACT  

Serum Carnitine Levels in Epileptic Children Before and During Treatment With Valproic Acid, Carbamazepine, and Phenobarbital
Castro-Gago et al.
J Child Neurol 1998;13:546-549.
ABSTRACT  

Carnitine Deficiency in Epilepsy: Risk Factors and Treatment
Coulter
J Child Neurol 1995;10:2S32-2S39.
ABSTRACT  

A Child With Valproic Acid-Associated Carnitine Deficiency and Carnitine-Responsive Cardiac Dysfunction
Bratton et al.
J Child Neurol 1992;7:413-416.
ABSTRACT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1991 American Medical Association. All Rights Reserved.